Hyperammonemia encephalopathy: An important cause of neurological deterioration following chemotherapy

References

• Summar M, Tuchman M. Proceedings of a consensus conference for the management of patients with urea cycle disorders. J Pediatr 2001; 138(1 Suppl)S6–S10
   Google Scholar
• Brusilow S W. Hyperammonemic encephalopathy. Medicine (Baltimore) 2002; 81: 240–249
   PubMed Web of Science ®Google Scholar
• Flannery D B, Hsia Y E, Wolf B. Current status of hyperammonemic syndromes. Hepatology 1982; 2: 495–506
   PubMed Web of Science ®Google Scholar
• Kaufman J J. Ammoniagenic coma following ureterosigmoidostomy. J Urol 1984; 131: 743–745
   PubMed Web of Science ®Google Scholar
• Drayna C J, Titcomb C P, Varma R R, Soergel K H. Hyperammonemic encephalopathy caused by infection in a neurogenic bladder. N Engl J Med 1981; 304: 766–768
   PubMed Web of Science ®Google Scholar
• Duarte J, Macias S, Coria F, Fernandez E, Claveria L E. Valproate-induced coma: case report and literature review. Ann Pharmacother 1993; 27: 582–583
   PubMed Web of Science ®Google Scholar
• Cuturic M, Abramson R K. Acute hyperammonemic coma with chronic valproic acid therapy. Ann Pharmacother 2005; 39: 2119–2123
   PubMed Web of Science ®Google Scholar
• Leonard J V, Kay J D. Acute encephalopathy and hyperammonaemia complicating treatment of acute lymphoblastic leukaemia with asparaginase. Lancet 1986; 1: 162–163
   PubMed Web of Science ®Google Scholar
• Mitchell R B, Wagner J E, Karp J E, Watson A J, Brusilow S W, Przepiorka D, et al. Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: review of nine cases. Am J Med 1988; 85: 662–667
   PubMed Web of Science ®Google Scholar
• Winter S S, Rose E, Katz R. Hyperammonemia after chemotherapy in an adolescent with hepatocellular carcinoma. J Pediatr Gastroenterol Nutr 1997; 25: 537–540
   PubMed Web of Science ®Google Scholar
• Liaw C C, Wang H M, Wang C H, Yang T S, Chen J S, Chang H K, et al. Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion 5-fluorouracil with the complication of dehydration and infection. Anticancer Drugs 1999; 10: 275–281
   PubMed Web of Science ®Google Scholar
• Espinos J, Rifon J, Perez-Calvo J, Nieto Y. Idiopathic hyperammonemia following high-dose chemotherapy. Bone Marrow Transplant 2006; 37: 899, Comment: Am J Med 1988;85:662 – 667
   PubMed Web of Science ®Google Scholar
• Davies S M, Szabo E, Wagner J E, Ramsay N K, Weisdorf D J. Idiopathic hyperammonemia: a frequently lethal complication of bone marrow transplantation. Bone Marrow Transplant 1996; 17: 1119–1125
   PubMed Web of Science ®Google Scholar
• Ho A Y, Mijovic A, Pagliuca A, Mufti G J. Idiopathic hyperammonemia syndrome following allogeneic peripheral blood progenitor cell transplantation (allo-PBPCT). Bone Marrow Transplant 1997; 20: 1007–1008
   PubMed Web of Science ®Google Scholar
• Tse N, Cederbaum S, Glaspy J A. Hyperammonemia following allogeneic bone marrow transplantation. Am J Hematol 1991; 38: 140–141
   PubMed Web of Science ®Google Scholar
• Xu S R, Yao E G, Dong Z R, Liu R S, Pan L, Lin F R, et al. Plasma ammonia in patients with acute leukaemia. Chin Med J (Engl) 1992; 105: 713–716
   PubMed Web of Science ®Google Scholar
• Yeh K H, Cheng A L. High-dose 5-fluorouracil infusional therapy is associated with hyperammonemia, lactic acidosis and encephalopathy. Br J Cancer 1997; 75: 464–465
   PubMed Web of Science ®Google Scholar
• Kim Y A, Chung H C, Choi H J, Rha S Y, Seong J S, Jeung H C. Intermediate dose 5-fluorouracil-induced encephalopathy. Jpn J Clin Oncol 2006; 36: 55–59
   PubMed Web of Science ®Google Scholar
• Snyder M J, Bradford W D, Kishnani P S, Hale L P. Idiopathic hyperammonemia following an unrelated cord blood transplant for mucopolysaccharidosis I. Pediatr Dev Pathol 2003; 6: 78–83
   PubMed Web of Science ®Google Scholar
• Gallardo D, Ferra C, Berlanga J J, Banda E D, Ponce C, Salar A, et al. Neurologic complications after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996; 18: 1135–1139
   PubMed Web of Science ®Google Scholar
• Lichtenstein G R, Yang Y X, Nunes F A, Lewis J D. Fatal hyperammonemia after orthotopic lung transplantation. Ann Intern Med 2000; 132: 283–287
   PubMed Web of Science ®Google Scholar
• Berry G T, Bridges N D, Nathanson K L, Kaplan P, Clancy R R, Lichtenstein G R, et al. Successful use of alternate waste nitrogen agents and hemodialysis in a patient with hyperammonemic coma after heart-lung transplantation. Arch Neurol 1999; 56: 481–484
   PubMed Web of Science ®Google Scholar
• Martinelli G, Peccatori F, Ullrich B, Ghielmini M, Roggero E, Goldhirsch A. Clinical manifestation of severe hyperammonemia in patients with multiple myeloma. Ann Oncol 1997; 8: 811
   PubMed Web of Science ®Google Scholar
• Kwan L, Wang C, Levitt L. Hyperammonemic encephalopathy in multiple myeloma. N Engl J Med 2002; 346: 1674–1675
   PubMed Web of Science ®Google Scholar
• Matsuzaki H, Uchiba M, Yoshimura K, Yoshida M, Akahoshi Y, Okazaki K, et al. Hyperammonemia in multiple myeloma. Acta Haematol 1990; 84: 130–134
   PubMed Web of Science ®Google Scholar
• Matsuzaki H, Hata H, Sonoki T, Matsuno F, Kuribayashi N, Yoshida M, et al. Serum amino acid disturbance in multiple myeloma with hyperammonemia. Int J Hematol 1995; 61: 131–137
   PubMed Web of Science ®Google Scholar
• Takimoto Y, Imanaka F, Hayashi Y, Morioka S. A patient with ammonia-producing multiple myeloma showing hyperammonemic encephalopathy. Leukemia 1996; 10: 918–919
   PubMed Web of Science ®Google Scholar
• Voorhies T M, Ehrlich M E, Duffy T E, Petito C K, Plum F. Acute hyperammonemia in the young primate: physiologic and neuropathologic correlates. Pediatr Res 1983; 17: 970–975
   PubMed Web of Science ®Google Scholar
• The Metabolic and Molecular Bases of Inherited Disease7th ed, C R Scriver, A L Beaudet, W S Sly, D Valle. McGraw-Hill, New York 1995
   Google Scholar
• Hourani B T, Hamlin E M, Reynolds T B. Cerebrospinal fluid glutamine as a measure of hepatic encephalopathy. Arch Intern Med 1971; 127: 1033–1036
   PubMed Web of Science ®Google Scholar
• Koenig H, Patel A. Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate. Arch Neurol 1970; 23: 155–160
   PubMed Web of Science ®Google Scholar
• Ardalan B, Glazer R. An update on the biochemistry of 5-fluorouracil. Cancer Treat Rev 1981; 8: 157–167
   PubMed Web of Science ®Google Scholar
• Pinedo H M, Peters G F. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988; 6: 1653–1664
   PubMed Web of Science ®Google Scholar
• Valik D. Encephalopathy, lactic acidosis, hyperammonemia and 5-fluorouracil toxicity. Br J Cancer 1998; 77: 1710–1712
   PubMed Web of Science ®Google Scholar
• Tuchman M, Lichenstein G R, Rajagopal B S, McCann M T, Furth E E, Bavaria J, et al. Hepatic glutamine synthetase deficiency in fatal hyperammonemia after lung transplantation. Ann Intern Med 1997; 127: 446–449
   PubMed Web of Science ®Google Scholar
• Gebhardt R, Lindros K, Lamers W H, Moorman A F. Hepatocellular heterogeneity in ammonia metabolism: demonstration of limited colocalization of carbamoylphosphate synthetase and glutamine synthetase. Eur J Cell Biol 1991; 56: 464–467
   PubMed Web of Science ®Google Scholar
• Gebhardt R. Metabolic zonation of the liver: regulation and implications for liver function. Pharmacol Ther 1992; 53: 275–354
   PubMed Web of Science ®Google Scholar
• Finkelstein J E, Hauser E R, Leonard C O, Brusilow S W. Late-onset ornithine transcarbamylase deficiency in male patients. J Pediatr 1990; 117: 897–902
   PubMed Web of Science ®Google Scholar
• Hourani B T, Hamlin E M, Reynolds T B. Cerebrospinal fluid glutamine as a measure of hepatic encephalopathy. Arch Intern Med 1971; 127: 1033–1036
   PubMed Web of Science ®Google Scholar
• Drogari E, Leonard J V. Late onset ornithine carbamoyl transferase deficiency in males. Arch Dis Child 1988; 63: 1363–1367
   PubMed Web of Science ®Google Scholar
• Cohn R M, Roth K S. Hyperammonemia, bane of the brain. Clin Pediatr (Phila) 2004; 43: 683–689
   PubMed Web of Science ®Google Scholar
• Chiong M A, Bennetts B H, Strasser S I, Wilcken B. Fatal late-onset ornithine transcarbamylase deficiency after coronary artery bypass surgery. Med J Aust 2007; 186: 418–419
   PubMed Web of Science ®Google Scholar
• Thakur V, Rupar C A, Ramsay D A, Singh R, Fraser D D. Fatal cerebral edema from late-onset ornithine transcarbamylase deficiency in a juvenile male patient receiving valproic acid. Pediatr Crit Care Med 2006; 7: 273–276
   PubMed Web of Science ®Google Scholar
• Rohininath T, Costello D J, Lynch T, Monavari A, Tuchman M, Treacy E P. Fatal presentation of ornithine transcarbamylase deficiency in a 62-year-old man and family studies. J Inherit Metab Dis 2004; 27: 285–288
   PubMed Web of Science ®Google Scholar
• Saudubray J M, Chappentier C. Clinical phenotypes: diagnosis/algorithms. Metabolic and Molecular Bases of Inherited Disease8th ed, C R Scriver, A L Beaudet, W S Sly, D Valle. McGraw-Hill, New York 2001; 1327
   Google Scholar
• Burton B K. Inborn errors of metabolism in infancy: a guide to diagnosis. Pediatrics 1998; 102: e69
   PubMed Web of Science ®Google Scholar
• Calvo M, Artuch R, Macià E, Luaces C, Vilaseca M A, Pou J, et al. Diagnostic approach to inborn errors of metabolism in an emergency unit. Pediatr Emerg Care 2000; 16: 405–408
   PubMed Web of Science ®Google Scholar
• Weiner D L. Metabolic emergencies. Textbook of Pediatric Emergency Medicine5th ed, G R Fleisher, S Ludwig, F M Henretig. Philadelphia, Lippincott 2006; 1193
   Google Scholar
• Ishibashi S, Nishimura H, Mizusawa H. 5-FU-induced acute leukoencephalopathy. Intern Med 2004; 43: 1009–1010
   PubMed Web of Science ®Google Scholar
• Hantson P, Grandin C, Duprez T, Nassogne M C, Guerit J M. Comparison of clinical, magnetic resonance and evoked potentials data in a case of valproic-acid-related hyperammonemic coma. Eur Radiol 2005; 15: 59–64
   PubMed Web of Science ®Google Scholar
• Ziyeh S, Thiel T, Spreer J, Klisch J, Schumacher M. Valproate-induced encephalopathy: assessment with MR imaging and 1H MR spectroscopy. Epilepsia 2002; 43: 1101–1105
   PubMed Web of Science ®Google Scholar
• Segura-Bruna N, Rodriguez-Campello A, Puente V, Roquer J. Valproate-induced hyperammonemic encephalopathy. Acta Neurol Scand 2006; 114: 1–7
   PubMed Web of Science ®Google Scholar
• Maestri N E, Clissold D, Brusilow S W. Neonatal onset ornithine transcarbamylase deficiency: a retrospective analysis. J Pediatr 1999; 134: 268–272
   PubMed Web of Science ®Google Scholar
• Batshaw M L, MacArthur R B, Tuchman M. Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr 2001; 138(1 Suppl)S46–S54, discussion S54 – S55
   Google Scholar
• Wong K Y, Wong S N, Lam S Y, Tam S, Tsoi N S. Ammonia clearance by peritoneal dialysis and continuous arteriovenous hemodiafiltration. Pediatr Nephrol 1998; 12: 589–591
   PubMed Web of Science ®Google Scholar
• Summar M. Current strategies for the management of neonatal urea cycle disorders. J Pediatr 2001; 138(1 Suppl)S30–S39
   PubMed Web of Science ®Google Scholar
• Brusilow S W, Horwich A L. Urea cycle enzymes. The Metabolic and Molecular Bases of Inherited Disease7th ed, C R Scriver, A L Beaudet, W S Sly, D Valle. McGraw-Hill, New York 1995; 1214–1215
   Google Scholar
• Berry G T, Kaplan P B, Lichtenstein G R. Hyperammonia possibly due to corticosteroids. Arch Neurol 2000; 57: 1085–10856
   PubMed Web of Science ®Google Scholar